Preferred Label : elacestrant;
Origin ID : C000626176;
UMLS CUI : C4682404;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3494990/fr/orserdu-elacestrant-cancer-du-sein
2024
false
false
false
France
elacestrant
insurance, health, reimbursement
treatment outcome
postmenopause
Activating ESR1 Gene Mutation
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
Metastatic Estrogen Receptor-Positive Breast Carcinoma
HER2/Neu Negative
administration, oral
selective estrogen receptor modulators
evaluation of the transparency committee
elacestrant
breast neoplasms
---
https://www.has-sante.fr/jcms/p_3527474/fr/orserdu-elacestrant-cancer-du-sein
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
estrogen receptor positive breast cancer
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
breast neoplasms, male
Metastatic Estrogen Receptor-Positive Breast Carcinoma
administration, oral
elacestrant
postmenopause
selective estrogen receptor modulators
evaluation of the transparency committee
breast neoplasms
Male Breast Carcinoma
elacestrant
---
https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
elacestrant
elacestrant
elacestrant
postmenopause
drug approval
europe
selective estrogen receptor modulators
selective estrogen receptor modulators
breast neoplasms
breast neoplasms, male
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
Metastatic Estrogen Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma
administration, oral
risk management
product surveillance, postmarketing
drug interactions
Activating ESR1 Gene Mutation
breast neoplasms
estrogen receptor alpha
drug evaluation, preclinical
---
